CABIO Biotech (Wuhan) Co. Ltd. Class A

As of June 30, 2026, CABIO Biotech (Wuhan) Co. Ltd. Class A carries a market capitalization of 1.79B, placing it among publicly traded companies globally. Its enterprise value stands at 1.62B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

CABIO Biotech (Wuhan) Co. Ltd. Class A's next confirmed earnings release is scheduled for October 30, 2026.

As of June 30, 2026, CABIO Biotech (Wuhan) Co. Ltd. Class A has 168.31M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, CABIO Biotech (Wuhan) Co. Ltd. Class A maintains a current ratio of 3.85, meaning it holds 3.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, CABIO Biotech (Wuhan) Co. Ltd. Class A recorded 2.82M in income tax expense.

As of the close on October 22, 2026, CABIO Biotech (Wuhan) Co. Ltd. Class A's stock has declined approximately 66.44% over the past 52 weeks. The 50-day moving average sits at 8.22, while the 200-day moving average is 14.27.

As of June 30, 2026, CABIO Biotech (Wuhan) Co. Ltd. Class A holds 351.48M in cash and equivalents against 176.07M in total debt, resulting in a net debt position of -18.55M. Total book value stands at 1.53B, with working capital of 545.91M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, CABIO Biotech (Wuhan) Co. Ltd. Class A paid dividends of 0.02 per share.

CABIO Biotech (Wuhan) Co. Ltd. Class A's most recent stock split took place on July 18, 2023 with a 5:7 split ratio.